Case report: Leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment (P5.403)

Conclusions:Cutaneous leukocytoclastic vasculitis is usually a self-limited, treatable problem which may be idiopathic or associated with medication or multiple disease states. Although alemtuzumab is an effective treatment for MS in many patients, it may be associated with potentially life-threatening thrombocytopenia and patients are closely followed. The present case adds another diagnosis, that of the more benign leukocytoclastic vasculitis, to the differential for post-treatment cutaneous change.Disclosure: Dr. Garten has nothing to disclose. Dr. Edwards has received personal compensation for activities with Biogen and Sanofi Genzyme as a speaker and/or consultant. Dr. Edwards has received research support from Biogen, Genentech, Sanofi-Genzyme, and Hoffmann-La Roche. Dr. Lezcano has nothing to disclose. Dr. Spiro has nothing to disclose. Dr. Siuta has nothing to disclose. Dr. Belcher has nothing to disclose.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Garten, L., Edwards, K., Lezcano, C., Spiro, J., Siuta, J., Belcher, S. Tags: Disease Modifying Therapy for Multiple Sclerosis: Risk Assessment and Safety Source Type: research